Last Updated: June 29, 2026

Suppliers and packagers for IMPLANON


✉ Email this page to a colleague

« Back to Dashboard


IMPLANON

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Organon IMPLANON etonogestrel IMPLANT;IMPLANTATION 021529 NDA Organon LLC 78206-145-01 1 BLISTER PACK in 1 CARTON (78206-145-01) / 1 IMPLANT in 1 BLISTER PACK 2021-06-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for IMPLANON

Last updated: June 4, 2026

Implanon (etonogestrel implant) suppliers: who manufactures, who supplies, and what supply-chain risks exist

Implanon is an etonogestrel contraceptive implant distributed under a Merck brand. Commercial supply has historically depended on a small set of implant manufacturing and packaging contractors plus Merck’s controlled distribution. Identifying specific “suppliers” requires mapping (1) the implant product holder and labeler, (2) implant manufacturing sites, (3) packaging/sterile handling steps, and (4) API and polymer/silicone-to-rod material sourcing.

Because only the drug name “Implanon” was provided and no jurisdiction, dosage form strength, or market (US/EU/UK/etc.) was specified, a complete supplier map cannot be produced with high confidence.

What company supplies Implanon and who is the product labeler?

Featured snippet answer: Implanon is supplied under Merck’s brand ownership and distribution, with manufacturing conducted by Merck and/or named contract manufacturing organizations on product labels and registration dossiers.

What does “supplier” mean for an implant contraceptive

Implanon supply chains typically break into these supplier categories:

  • Product/labeler (marketing authorization holder and US FDA labeler)
  • Implant drug-device manufacturing (rod + drug loading + assembly)
  • Sterile packaging and distribution labeling
  • Etogestrel API supply
  • Device materials supply (rod, polymer components, inert excipients)
  • Logistics contractors (cold chain rarely required, but controlled handling may apply)

Which manufacturers make the etonogestrel implant product (Implanon) in practice?

Featured snippet answer: The manufacturing footprint is not the same across all geographies; implant assembly and packaging are commonly performed at dedicated device-capable sites controlled by the brand owner and/or validated contract manufacturers.

Typical manufacturing steps that determine supplier list size

  • Drug loading of etonogestrel into an implantable matrix or rod system
  • Assembly into an implant delivery component
  • Quality control release testing (drug content uniformity, implant dimensions)
  • Packaging in an applicator system with patient leaflet inserts
  • Distribution under controlled batch traceability

Who supplies etonogestrel API for contraceptive implants?

Featured snippet answer: Etongestrel API sourcing is usually handled by large-scale steroid or progestin API suppliers for branded contraceptives; the exact vendor list is product- and geography-specific.

API supply-chain dependencies

  • Steroid intermediate sourcing (precursor supply continuity is often the highest risk)
  • GMP compliance and drug substance traceability
  • Change control: API supplier switches can trigger comparability work and regulatory notifications

What packaging and device applicator suppliers support Implanon?

Featured snippet answer: Device applicator and packaging are typically supplied by device manufacturing contractors or integrated device operations at the brand owner’s manufacturing network.

Why applicator suppliers matter

Implanon is a drug-device combination:

  • Applicator reliability affects usability and market acceptance
  • Device component material specs must match implant dimensions and insertion requirements
  • Tamper-evident and batch-traceable packaging is a release gate

How do supplier substitutions work if an implant contractor changes?

Featured snippet answer: Substitutions are managed via change control with comparability testing, batch release validation, and regulatory filing depending on jurisdiction.

Common triggers for supplier changes

  • Contract manufacturing relocation
  • Yield or capacity constraints at an implant assembly line
  • API sourcing changes due to plant shutdowns
  • Packaging line conversions (label language, NDC updates, blister changes)

What supply-chain risks exist for etonogestrel implant products?

Featured snippet answer: The biggest practical risks are capacity bottlenecks in implant assembly/packaging and API precursor continuity, not retail distribution.

Risk pattern by layer

  • API layer: upstream precursor risk and GMP issues
  • Device layer: applicator component supply constraints
  • Packaging: label/leaflet language conversions and serialization controls
  • Release: slow release testing or QC capacity limits

Key Takeaways

  • Implanon supply is anchored by Merck’s brand ownership and distribution, with manufacturing and packaging performed through Merck sites and/or validated contractors.
  • A reliable “supplier list” depends on the specific market (US vs EU vs UK) and the implant strength/form (standard Implanon vs region-specific packaging).
  • For implant contraceptives, the most important supplier categories are implant assembly, drug substance (etonogestrel) API, applicator/device components, and packaging/labeling release.

FAQs

  1. Who is the manufacturer of Implanon in the US market?
  2. Is Implanon manufactured by Merck or by contract manufacturers?
  3. Who supplies etonogestrel API for contraceptive implants?
  4. What companies make the Implanon applicator and insertion device components?
  5. How does a change in implant manufacturing site affect regulatory status and supply timelines?

References

  1. No citable sources were provided in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.